A randomized, multicenter, double blind, phase 2B study of Igv-001, an autologous cell immunotherapy with antisense oligo IMV-001 targeting IGF-1R, vs placebo, in newly diagnosed glioblastoma patients Meeting Abstract
| Authors: | Lee, I.; Judy, K.; Schulder, M.; Hanft, S.; Evans, L.; Wu, J.; Aulakh, S.; Wong, E.; Agarwal, V.; Ramakrishna, R.; Elder, J. B.; Gill, B.; Quiǹƒones-Hinojosa, A.; Brennan, C.; Perez-Olle, R.; Diwanji, M.; Pennock, G.; Scott, C.; Andrews, D.; Boockvar, J. |
| Abstract Title: | A randomized, multicenter, double blind, phase 2B study of Igv-001, an autologous cell immunotherapy with antisense oligo IMV-001 targeting IGF-1R, vs placebo, in newly diagnosed glioblastoma patients |
| Meeting Title: | 28th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) |
| Journal Title: | Neuro-Oncology |
| Volume: | 25 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Nov 15-19 |
| Meeting Location: | Vancouver, Canada |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | v260 |
| Language: | English |
| ACCESSION: | WOS:001115245401210 |
| PROVIDER: | wos |
| DOI: | 10.1093/neuonc/noad179.0999 |
| Notes: | Meeting Abstract: RTID-08 -- Source: Wos |
